PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer-Reference-Cited by-同舟云学术

PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer

Published:2017-03-14 Issue:470 Volume:10 Page:
ISSN:1945-0877
Container-title:Science Signaling
language:en
Short-container-title:Sci. Signal.

Author:

Caromile Leslie Ann¹^ORCID,Dortche Kristina¹,Rahman M. Mamunur¹,Grant Christina L.¹,Stoddard Christopher²^ORCID,Ferrer Fernando A.³,Shapiro Linda H.¹^ORCID

Affiliation:

1. Center for Vascular Biology, University of Connecticut Health Center, Farmington, CT 06030, USA.

2. Department of Genetics and Developmental Biology, University of Connecticut Health Center, Farmington, CT 06030, USA.

3. Department of Urology, New York Medical College, Valhalla, NY 10595, USA.

Abstract

Prostate-specific membrane antigen is both a diagnostic marker and an indicator for personalized therapeutic intervention for cancer patients.

Funder

National Cancer Institute

Prostate Cancer Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Cell Biology,Molecular Biology,Biochemistry

Reference87 articles.

1. Cancer treatment and survivorship statistics, 2012

2. Targeting the androgen receptor pathway in prostate cancer

3. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone

4. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells

5. The Insulin-Like Growth Factor-I Receptor Kinase Inhibitor, NVP-ADW742, Sensitizes Small Cell Lung Cancer Cell Lines to the Effects of Chemotherapy

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-Specific Membrane Antigen Biology and Pathophysiology in Prostate Carcinoma, an Update: Potential Implications for Targeted Imaging and Therapy;International Journal of Molecular Sciences;2024-09-09

2. PSMA-reactive NB7 single domain antibody fragment: A potential scaffold for developing prostate cancer theranostics;Nuclear Medicine and Biology;2024-07

3. Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison;Molecular Cancer;2024-04-16

4. Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology;Trends in Cancer;2024-04

5. Structure-activity relationship study of mesyl and busyl phosphoramidate antisense oligonucleotides for unaided and PSMA-mediated uptake into prostate cancer cells;Frontiers in Chemistry;2024-03-04